Dr. Wysock on the Role of Cytoreductive Nephrectomy in RCC

James Wysock, MD
Published: Thursday, Feb 15, 2018


James Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses the role of cytoreductive nephrectomy in renal cell carcinoma (RCC).

Cytoreductive nephrectomy surgically removes most of the cancer in a patient, with the understanding that some will remain. However, as a treatment for patients with RCC, Wysock says that this approach is beneficial—demonstrating an improvement in overall survival in trials of patients with advanced or metastatic RCC.

Surgical resection remains the standard of care for the majority of patients with RCC, but ongoing studies have begun to address the question of whether additional therapy in conjunction with cytoreductive nephrectomy could create more durable and long-lasting responses.

James Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses the role of cytoreductive nephrectomy in renal cell carcinoma (RCC).

Cytoreductive nephrectomy surgically removes most of the cancer in a patient, with the understanding that some will remain. However, as a treatment for patients with RCC, Wysock says that this approach is beneficial—demonstrating an improvement in overall survival in trials of patients with advanced or metastatic RCC.

Surgical resection remains the standard of care for the majority of patients with RCC, but ongoing studies have begun to address the question of whether additional therapy in conjunction with cytoreductive nephrectomy could create more durable and long-lasting responses.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x